Efficacy of the Nanodropper Device on Intraocular Pressure in Patients With Glaucoma

a study on Glaucoma High Blood Pressure Ocular Hypertension

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco, California
Dates
study started
estimated completion
Principal Investigator
by Julius Oatts, MD
Headshot of Julius Oatts
Julius Oatts

Description

Summary

Glaucoma is the leading cause of irreversible blindness worldwide. Previous studies demonstrate that smaller eye drops used in the treatment of glaucoma are just as efficacious as their larger counterparts. The proposed study hopes to demonstrate the non-inferiority of using Nanodropper to lower intraoccular pressure (IOP) in glaucoma patients compared to standard of care eye drops.

Details

The proposed study strives to demonstrate the non-inferiority of using Nanodropper to lower IOP in glaucoma patients compared to standard of care (SOC) eye drops in a randomized trial. Primary Aim: Demonstrate non-inferiority of using Nanodropper to lower IOP compared to standard of care eye drops in glaucoma patients. Stable glaucoma participants and ocular hypertension participants of ages 18+ will be randomized to either use Nanodropper for eye drop administration in both eyes OR administer drops regularly (standard of care) in both eyes. Participants will be followed-up at 1 month and 3 months.

Keywords

Glaucoma, Ocular Hypertension, Open Angle Glaucoma, Open-Angle Glaucoma, Nanodropper

Eligibility

You can join if…

Open to people ages 18 years and up

  1. 18 years old or older
  2. Diagnosis of open-angle glaucoma (OAG) or ocular hypertension (OHT)
  3. Use of prostaglandin analogue (PGA) eye drop
  4. Stable disease status (no visual field loss progression or increase in IOP-lowering medications in the last 6 months)

You CAN'T join if...

  1. Uncontrolled glaucoma
  2. Have had eye surgery (including laser procedures) within the past six months
  3. Have a diagnosis of acute angle-closure glaucoma and/or other retinal diseases
  4. Use of non-PGA class of IOP-lowering medication

Location

  • University of California, San Francisco accepting new patients
    San Francisco California 94143 United States

Lead Scientist at UCSF

  • Julius Oatts, MD
    Dr. Julius Oatts is a pediatric ophthalmologist and a pediatric glaucoma specialist who specializes in the medical and surgical treatment of children with common eye diseases as well as glaucoma, a rare condition in children. His research focuses on the most accurate ways to measure eye pressure in children.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Francisco
ID
NCT05273385
Study Type
Interventional
Participants
Expecting 80 study participants
Last Updated
Contact us about this trial